Adicet stock jumps 10 percent on FDA fast track status for ADI-270
| ACET Stock | USD 1.09 0.10 10.10% |
Slightly above 54% of Adicet Bio's private investors are presently thinking to get in. The analysis of overall sentiment of trading Adicet Bio stock suggests that some investors are interested at this time. Adicet Bio's investing sentiment can be driven by a variety of factors including economic data, Adicet Bio's earnings reports, geopolitical events, and overall market trends.
Adicet |
Adicet Bio stock climbed 10 percent after the company received FDA fast track designation for its CAR-T cell therapy ADI-270 in the treatment of kidney cancer. Read more here.
Read at seekingalpha.com
 |
Adicet Bio Fundamental Analysis
We analyze Adicet Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adicet Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adicet Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Adicet Bio is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Adicet Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adicet Bio stock to make a market-neutral strategy. Peer analysis of Adicet Bio could also be used in its relative valuation, which is a method of valuing Adicet Bio by comparing valuation metrics with similar companies.
Peers
Adicet Bio Related Equities
| VOR | Vor Biopharma | 31.82 | ||||
| TNYA | Tenaya Therapeutics | 7.04 | ||||
| AADI | Aadi Bioscience | 4.60 | ||||
| AGIO | Agios Pharm | 4.19 | ||||
| ACRV | Acrivon Therapeutics, | 2.57 | ||||
| AVTE | Aerovate Therapeutics | 0.75 | ||||
| BCYC | Bicycle Therapeutics | 0.07 | ||||
| IGMS | IGM Biosciences | 0.91 | ||||
| NKTX | Nkarta | 1.60 | ||||
| ANEB | Anebulo Pharmaceuticals | 1.82 | ||||
| ALEC | Alector | 1.94 | ||||
| PLRX | Pliant Therapeutics | 2.59 | ||||
| KROS | Keros Therapeutics | 2.86 | ||||
| GLUE | Monte Rosa | 3.91 | ||||
| STOK | Stoke Therapeutics | 4.09 | ||||
| EWTX | Edgewise Therapeutics | 4.18 | ||||
| CGEM | Cullinan Oncology | 7.10 |
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.